One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
暂无分享,去创建一个
E. Antman | R. Giugliano | E. Braunwald | H. White | D. Morrow | S. Murphy | C. McCabe | K. Fox
[1] S. Yusuf,et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. , 2005, JAMA.
[2] G. Uijen,et al. Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial , 2002, Circulation.
[3] W. Frishman. Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 AnalysisNallamothu BK, for the NRMI Investigators (Ann Arbor VA Med Ctr, Mich; et al) Circulation 111:761–767, 2005§ , 2006 .
[4] H. Heidbuchel,et al. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial , 2002, Circulation.
[5] F. Fernández‐Avilés,et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial , 2004, The Lancet.
[6] E. Antman,et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.
[7] E. Antman,et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. , 2007, European heart journal.
[8] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[9] J. Gore,et al. Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction? , 2007, Circulation.
[10] K. Coyne,et al. Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II) , 2002 .
[11] J. Ware,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.
[12] Christopher E. Buller,et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Journal of the American College of Cardiology.
[13] Harlan M Krumholz,et al. Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 Analysis , 2005, Circulation.
[14] D. Grobbee,et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial , 2002, The Lancet.
[15] David P Miller,et al. Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy , 2006, Circulation.
[16] Deepak L. Bhatt,et al. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.
[17] K. Coyne,et al. Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II) , 2001, Circulation.
[18] E. Antman. The Search for Replacements for Unfractionated Heparin , 2001, Circulation.
[19] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .
[20] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[21] J. Mega,et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial , 2009, The Lancet.
[22] Frans Van de Werf,et al. MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION (ENDING) , 2009 .
[23] H. Krumholz,et al. Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Gaps, Barriers, and Implications , 2007, Circulation.
[24] Timi Study,et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction , 2006 .
[25] E. Antman,et al. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. , 2010, European heart journal.
[26] R. Diaz,et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. , 2004, American heart journal.
[27] Timi Study,et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .
[28] E. Antman,et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. , 2003, Journal of the American College of Cardiology.
[29] G. Lamas,et al. Focused Update of the ACC / AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2007 .
[30] R. Collins,et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. , 1997, The New England journal of medicine.